# Nattokinase Supplementation and Hemostatic Factors

Study · id `cardio:ct-nct02913170` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02913170](<https://clinicaltrials.gov/study/NCT02913170>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02913170

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT02913170. Randomized; triple masking; primary purpose supportive care. Start 2015-05 (registry gives no type); primary completion 2016-09 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose supportive care
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT02913170, source copy `cardio:ctgov-nct02913170-2016-09-23`, retrieved 2026-10-31)
- Start date: 2015-05 (registry gives no type) (ClinicalTrials.gov record NCT02913170, source copy `cardio:ctgov-nct02913170-2016-09-23`, retrieved 2026-10-31)
- Primary completion: 2016-09 (actual) (ClinicalTrials.gov record NCT02913170, source copy `cardio:ctgov-nct02913170-2016-09-23`, retrieved 2026-10-31)
- Completion: 2016-09 (actual) (ClinicalTrials.gov record NCT02913170, source copy `cardio:ctgov-nct02913170-2016-09-23`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT02913170, source copy `cardio:ctgov-nct02913170-2016-09-23`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02913170-2016-09-23`, retrieved 2026-10-31)

## The registry's words

- Brief title: Nattokinase Supplementation and Hemostatic Factors
- Condition: Hypercholesterolemia
- Intervention (Dietary supplement): Nattokinase
- Intervention (Dietary supplement): Placebo
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: 4eaef5d6f94aaf0337456288d6bdcbe34cbb1e382467d79173a4874c9525e9ea
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
